Proceeds will support continued advancement of the company's pipeline, which includes programs addressing elusive targets within the RAS pathway such as KRASG12C(GTP) and other specific tumorigenic mutants of RAS.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

700 Saginaw Dr.
Redwood City, CA 94063
USA

Phone

(650) 481-6801

Website

www.revolutionmedicines.com

Email Address

[email protected]

Overview

Revolution Medicines (Nasdaq: RVMD) discovers and develops important new medicines for cancer patients by translating frontier oncology targets--proteins that drive the growth of cancers or that control immune responses that can defeat them.

Profile

Social Media

Revolution Medicines Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Mark Goldsmith

Chief Operating Officer

Margaret Horn

Vice President

Adrian Gill

Vice President

Richard Hansen

Vice President

Walter Reiher

Vice President

Jan Smith

Vice President

Xiaolin Wang

VP - Finance

Jack Anders

VP - Human Resources

Luan Wilfong

VP - R & D

Steve Kelsey

Browse more venture capital transactions:

Prev: 7/11/2019: TrustArc venture capital transaction
Next: 7/11/2019: Remitly venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary